S. Zaheer1, L. E. Kuo1, J. C. Morrison1, H. Wachtel1, G. C. Karakousis1, D. L. Fraker1, R. R. Kelz1 1University Of Pennsylvania,Department Of Endocrine And Oncologic Surgery,Philadelphia, PA, USA
Introduction:
Thyroid cancer is the most common endocrine malignancy. Surgical resection and TSH suppression are amongst the mainstays of treatment for thyroid cancer. As such, the presence of thyroid cancer in the setting of hyperthyroidism poses an interesting clinical scenario. It has been suggested that thyroid cancer associated with Graves’ disease has a more aggressive course than is typically seen. We sought to examine the relationship between thyroid cancer and hyperthyroidism with attention to the cancer characteristics.
Methods:
Thyroid surgery patients enrolled in our institutional prospective endocrine surgery registry from 2007 to 2013 were identified for inclusion in the study. Patients on synthyroid, TSH> 4.0 mIU/L or missing information on TSH were excluded. Patients were classified as hyperthyroid (documented hyperthyroidism or TSH< 0.4 mIU/L) or euthyroid (TSH b/w 0.4-4.0 mIU/L). The primary outcome of interest was any well-differentiated thyroid cancer. Tumor characteristics were examined as secondary outcomes. Univariate analyses were performed to examine the association of hyperthyroidism and thyroid cancer using the Wilcoxon ranksum, Fisher’s exact and Chi-square tests, as appropriate
Results:
Of 752 patients included in the study, there were 271 (36%) patients with pre-operative hyperthyroidism and 385 (51%) patients with thyroid cancer. Age, sex and ethnicity were evenly distributed in the groups. Patients with hyperthyroidism had reduced incidence of cancer compared to euthyroid patients (40% vs. 58% respectively, p<0.01). Patients with hyperthyroidism were found to have similar tumors in most cases with less aggressive features noted in certain characteristics when compared to the euthyroid patients (see Table).
Conclusion:
TSH suppression is one of the mainstays of treatment for patients with thyroid cancer. Despite this, thyroid cancer can present in the setting of hyperthyroidism. When cancer was identified, the tumors were more commonly smaller than those observed in euthyroid patients. The role of TSH suppression, antithyroid medications and exposure to therapeutic doses of radioactive iodine in the pre-operative setting may influence the types of cancers identified in patients with hyperthyroidism.